, 2005); (2) binding sites for the multivalent transcription regulatory factor CTCF (Ohlsson et al., 2001), within close proximity of the repeats (Filippova et al., 2001); and (3) bidirectional transcription typically encompassing the repeat itself (Batra et al., 2010). These features suggest that certain epigenetic processes and chromatin regulatory pathways may be shared in common between different repeat diseases. As the SCA7 CAG repeat

Veliparib order is the most unstable of all the CAG/polyQ repeat loci, and the SCA7 CAG repeat is closely flanked by two functional CTCF binding sites, the SCA7 CAG repeat is among the repeat disease loci likely to display this constellation of genomic features. In light of the importance of ataxin-7 normal function for SCA7 disease pathogenesis and potentially for global transcription regulation, we initiated a series of studies aimed at understanding how ataxin-7 gene expression is regulated. The ataxin-7 CAG repeat tract and the start site of translation are both located in exon 3, which is flanked by two functional

CTCF binding sites (Filippova et al., 2001). CTCF is a highly conserved 11 zinc-finger protein that mediates a variety of transcription regulatory functions, including selleck chemical transcription activation, transcription repression, insulator-boundary domain formation, and genomic imprinting (Phillips and Corces, 2009). When we analyzed

the ataxin-7 repeat region, we discovered evidence for an alternative promoter just 5′ to exon 3, and identified an antisense non-coding RNA, SCAANT1 (for spinocerebellar ataxia-7 MTMR9 antisense noncoding transcript 1) that is convergently transcribed across exon 4, exon 3, and the alternative promoter. To understand the role of CTCF in regulating ataxin-7 transcription, we introduced ataxin-7 minigenes, containing the ataxin-7 repeat region with a CAG repeat expansion, into transgenic mice. Studies of these transgenic mice and of human retinoblastoma cell lines revealed that CTCF binding is required for production of SCAANT1, and that loss of SCAANT1 expression de-repressed ataxin-7 sense transcription from the alternative promoter. Although SCAANT1 expression in trans did not reduce ataxin-7 alternative sense promoter activity in vitro or in vivo, convergent transcription of SCAANT1 in cis led to repression that was accompanied by posttranslational modification of histones. Our studies reveal a regulatory pathway that links CTCF transactivation of antisense noncoding RNA with repression of the corresponding sense transcript.